HomeCompareLLY vs ALGN

LLY vs ALGN: Dividend Comparison 2026

LLY yields 0.70% · ALGN yields 1.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LLY wins by $1.52M in total portfolio value
10 years
LLY
LLY
● Live price
0.70%
Share price
$886.67
Annual div
$6.23
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.54M
Annual income
$1,207,534.19
Full LLY calculator →
ALGN
ALGN
● Live price
1.20%
Share price
$166.26
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$130.06
Full ALGN calculator →

Portfolio growth — LLY vs ALGN

📍 LLY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLLYALGN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LLY + ALGN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LLY pays
ALGN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LLY
Annual income on $10K today (after 15% tax)
$59.72/yr
After 10yr DRIP, annual income (after tax)
$1,026,404.06/yr
ALGN
Annual income on $10K today (after 15% tax)
$102.25/yr
After 10yr DRIP, annual income (after tax)
$110.55/yr
At 15% tax rate, LLY beats the other by $1,026,293.51/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LLY + ALGN for your $10,000?

LLY: 50%ALGN: 50%
100% ALGN50/50100% LLY
Portfolio after 10yr
$779.5K
Annual income
$603,832.13/yr
Blended yield
77.46%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on LLY right now

LLY
Analyst Ratings
33
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$1,243.95
+40.3% upside vs current
Range: $985.00 — $1,350.00
Altman Z
7.7
Piotroski
6/9
ALGN
Analyst Ratings
24
Buy
7
Hold
2
Sell
Consensus: Buy
Price Target
$197.30
+18.7% upside vs current
Range: $140.00 — $220.00
Altman Z
4.9
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LLY buys
0
ALGN buys
0
No recent congressional trades found for LLY or ALGN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLLYALGN
Forward yield0.70%1.20%
Annual dividend / share$6.23$2.00
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%0%
Portfolio after 10y$1.54M$21.4K
Annual income after 10y$1,207,534.19$130.06
Total dividends collected$1.49M$1.3K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuyBuy
Analyst price target$1,243.95$197.30

Year-by-year: LLY vs ALGN ($10,000, DRIP)

YearLLY PortfolioLLY Income/yrALGN PortfolioALGN Income/yrGap
1← crossover$10,841$140.53$10,820$120.29+$21.00LLY
2$11,884$284.74$11,699$121.65+$185.00LLY
3$13,299$583.47$12,641$122.92+$658.00LLY
4$15,451$1,220.47$13,650$124.13+$1.8KLLY
5$19,183$2,650.30$14,731$125.27+$4.5KLLY
6$26,676$6,150.32$15,889$126.34+$10.8KLLY
7$44,530$15,986.45$17,128$127.36+$27.4KLLY
8$97,527$49,880.25$18,455$128.31+$79.1KLLY
9$308,551$204,197.51$19,876$129.21+$288.7KLLY
10$1,537,684$1,207,534.19$21,398$130.06+$1.52MLLY

LLY vs ALGN: Complete Analysis 2026

LLYHealthcare

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Full LLY Calculator →

ALGNStock

Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go; and non-case products include retention products, Invisalign training fees, and sales of ancillary products, such as cleaning material, and adjusting tools used by dental professionals during the course of treatment. The Scanners and Services segment offers iTero scanner, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides computer-aided design and computer-aided manufacturing services; ancillary products, such as disposable sleeves for the wand; iTero model and dies; third party scanners and digital scans; Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan. The company sells its products in the United States, Switzerland, China, and internationally. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.

Full ALGN Calculator →
📬

Get this LLY vs ALGN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LLY vs SCHDLLY vs JEPILLY vs OLLY vs KOLLY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.